Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001641172-25-023745
Filing Date
2025-08-14
Accepted
2025-08-14 09:00:48
Documents
52
Period of Report
2025-06-30

Document Format Files

Seq Description Document Type Size
1 10-Q form10-q.htm   iXBRL 10-Q 999569
2 EX-10.1 ex10-1.htm EX-10.1 70532
3 EX-10.2 ex10-2.htm EX-10.2 121792
4 EX-10.4 ex10-4.htm EX-10.4 121996
5 EX-31.1 ex31-1.htm EX-31.1 10939
6 EX-31.2 ex31-2.htm EX-31.2 18186
7 EX-32.1 ex32-1.htm EX-32.1 7103
8 EX-32.2 ex32-2.htm EX-32.2 7237
  Complete submission text file 0001641172-25-023745.txt   5292944

Data Files

Seq Description Document Type Size
9 XBRL SCHEMA FILE thar-20250630.xsd EX-101.SCH 34287
10 XBRL CALCULATION FILE thar-20250630_cal.xml EX-101.CAL 30487
11 XBRL DEFINITION FILE thar-20250630_def.xml EX-101.DEF 161642
12 XBRL LABEL FILE thar-20250630_lab.xml EX-101.LAB 351043
13 XBRL PRESENTATION FILE thar-20250630_pre.xml EX-101.PRE 274877
54 EXTRACTED XBRL INSTANCE DOCUMENT form10-q_htm.xml XML 690547
Mailing Address 245 MAIN STREET SUITE 204 CHESTER NJ 07930
Business Address 1200 ROUTE 22 EAST BRIDGEWATER NJ 08807 302-743-2995
Tharimmune, Inc. (Filer) CIK: 0001861657 (see all company filings)

EIN.: 842642541 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-41210 | Film No.: 251214734
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)